Fda pediatric exclusivity determinations 2024?

I can help with what pediatric exclusivity determinations are and how to find the 2024 list, but I don’t have the exact 2024 determinations memorized. Here’s how you can get the official, up-to-date list from FDA:

What “pediatric exclusivity” means
- A 6-month period of additional market exclusivity can be granted if a sponsor completes FDA-mrompted pediatric studies (under PREA/BPCA) and FDA determines the studies are adequate and results are reported.
- The exclusivity typically applies to the same drug product (the same active ingredient, dosage form, and route) or labeling/indication covered by the pediatric data.

Where to find the 2024 determinations
- FDA’s Pediatric Exclusivity page (CDER/OPQ, etc.): Look for a section or table titled something like “Pediatric Exclusivity Determinations.” They publish determinations by year.
- Likely URL format (searchable on FDA’s site): fd a.gov/drugs/development-resources/pediatric-exclusivity
- Federal Register notices: Occasionally, updates or confirmations related to exclusivity are noted in relevant Federal Register postings.
- FDA press releases or CDER news: Some determinations are announced via the FDA press office or CDER updates.

What you’ll typically see in a 2024 list
- Product name (drug and/or indication)
- Sponsor name
- NDA/BLA number or equivalent
- Date of FDA determination granting pediatric exclusivity
- Any notes about the scope (e.g., which indication or formulation is covered)

If you’d like, I can:
- Help you interpret a list you already have (explain what each entry means, scope of exclusivity, etc.).
- Compile a summarized table if you provide the names or download the 2024 list and paste it here.
- Answer specific questions about how pediatric exclusivity interacts with other exclusivities or labeling changes.

Would you like me to guide you step-by-step to the FDA page now, or do you have particular drug names from 2024 you want explained?